

**Supplementary Table 1.** Reclassification for the atherosclerotic cardiovascular disease events in intermediate-risk participants stratified by sex.

Models	Event NRI (95% CI)	Nonevent NRI (95% CI)	Total NRI (95% CI)
<b>Men</b>			
The CSC model*			
+ Family history of CVD	0.068 (-0.026, 0.183)	-0.053 (-0.082, -0.025)	0.015 (-0.085, 0.130)
+ Overweight/obesity	0.159 (0.019, 0.304)	-0.040 (-0.069, -0.009)	0.119 (-0.031, 0.264)
+ Central obesity	0.068 (0.000, 0.613)	-0.050 (-0.073, -0.026)	0.018 (-0.055, 0.111)
+ TG $\geq$ 200 mg/dL	0.023 (0.000, 0.075)	-0.013 (-0.031, 0.005)	0.010 (-0.026, 0.063)
+ hs-CRP $\geq$ 2.0 mg/L	0.091 (0.020, 0.192)	-0.027 (-0.046, -0.011)	0.064 (-0.014, 0.163)
+ Lp(a) $\geq$ 50 mg/dL	0.000 (0.000, 0.000)	-0.004 (-0.013, 0.004)	-0.004 (-0.013, 0.004)
Replace LDL-C with non-HDL-C	0.136 (0.045, 0.244)	-0.077 (-0.101, -0.052)	0.059 (-0.036, 0.164)
+ $\geq$ 1 risk-enhancing factors	0.114 (0.025, 0.213)	-0.020 (-0.043, 0.001)	0.094 (0.003, 0.202)
+ $\geq$ 2 risk-enhancing factors	0.227 (0.085, 0.369)	-0.057 (-0.093, -0.019)	0.170 (0.023, 0.312)
<b>Women</b>			
The CSC model*			
+ Family history of CVD	0.020 (0.000, 0.069)	0.012 (0.001, 0.024)	0.033 (0.003, 0.082)
+ Overweight/obesity	0.082 (-0.049, 0.204)	0.004 (-0.028, 0.037)	0.086 (-0.046, 0.217)
+ Central obesity	0.041 (-0.068, 0.157)	0.008 (-0.019, 0.034)	0.049 (-0.066, 0.164)
+ TG $\geq$ 200 mg/dL	0.000 (0.000, 0.000)	-0.004 (-0.020, 0.011)	-0.004 (-0.020, 0.011)
+ hs-CRP $\geq$ 2.0 mg/L	0.122 (0.038, 0.220)	0.001 (-0.031, 0.032)	0.124 (0.031, 0.229)
+ Lp(a) $\geq$ 50 mg/dL	0.041 (-0.038, 0.121)	0.004 (-0.019, 0.030)	0.045 (-0.035, 0.126)
Replace LDL-C with non-HDL-C	0.000 (-0.058, 0.067)	-0.009 (-0.025, 0.009)	-0.009 (-0.071, 0.061)
+ $\geq$ 1 risk-enhancing factors	0.000 (-0.076, 0.086)	0.022 (0.000, 0.043)	0.022 (-0.056, 0.112)
+ $\geq$ 2 risk-enhancing factors	0.163 (0.000, 0.333)	0.028 (-0.014, 0.070)	0.191 (0.025, 0.367)

Abbreviations: hs-CRP: high-sensitivity C-reactive protein; Lp(a): Lipoprotein(a); non-HDL-C: non-high-density lipoprotein cholesterol; NRI: net reclassification improvement; TG: triglycerides.

\* The Chinese Society of Cardiology-recommended clinical risk assessment tool stratified by sex.